Clinical Trial Update: Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) [Phase 1, Phase 2]

View source ↗

Summary

This entry outlines a Phase 1/2 clinical trial (MARALL) evaluating monoclonal antibodies for recurrent or refractory B-cell acute lymphoblastic leukemia, sponso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Snippet

Sponsor: Queen Mary University of London | Conditions: Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | Phase 1, Phase 2 | Status: UNKNOWN